Ruxolitinib for Cancer Cachexia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
- Status
- COMPLETED
- Phase
- PHASE2
Itacitinib for the Prevention of Graft Versus Host Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE2
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
- Status
- COMPLETED
- Phase
- PHASE1
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
- Status
- COMPLETED
- Phase
- PHASE1
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Status
- WITHDRAWN
- Phase
- PHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Status
- RECRUITING
- Phase
- PHASE2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
- Status
- COMPLETED
- Phase
- PHASE2
Study of INCB086550 in Select Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2